CJC-1295 vs HCG
Head-to-head comparison of CJC-1295 and HCG for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Hcg |
|---|---|---|
| Category | Growth Hormone Secretagogue | Hormonal / Reproductive |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | HCG binds to the LH/CG receptor (LHCGR) on Leydig cells and theca cells with high affinity. In males, this stimulates intratesticular testosterone production, spermatogenesis, and maintains testicular volume. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved for anovulation/infertility, hypogonadotropic hypogonadism, prepubertal cryptorchidism. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: injection site reactions, headache, fatigue, mood changes; Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 250-500 IU per injection (750-1500 IU/week) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | 3 times per week |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~36,700 g/mol (glycoprotein) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~24-36 hours |
Overview
CJC-1295 and HCG are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
HCG — Mechanism & Evidence
Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone (MW ~36,700 g/mol) composed of an alpha subunit (shared with LH, FSH, TSH) and a unique beta subunit. Naturally produced by placental trophoblasts during pregnancy, pharmaceutical HCG binds LH/CG receptors in the gonads, stimulating testosterone production in Leydig cells and progesterone in the corpus luteum. It is FDA-approved for multiple reproductive indications and is widely used off-label to maintain testicular function during testosterone replacement therapy (TRT).
Key claims: Maintains testicular function during TRT; Preserves fertility during testosterone use; Triggers ovulation in fertility treatment.
Shared Research Applications
These peptides target different research areas. CJC-1295 focuses on Anti-Aging, Body Composition, while HCG targets Reproductive Health, Hormonal.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
HCG: Common: injection site reactions, headache, fatigue, mood changes Males: gynecomastia (from estradiol conversion), water retention, testicular discomfort Females: ovarian hyperstimulation syndrome (OHSS) — potentially serious
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.